EMA and FDA Set Common Principles for AI in Medicine Development
The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have collaboratively outlined ten principles aimed at enhancing the use of artificial intelligence (AI) in the lifecycle of medicines. This initiative marks a significant step towards improving the integration of AI technologies in drug development.
Guiding Principles of AI in Medicines Lifecycle
These ten principles provide comprehensive guidance on the application of AI across various stages of a medicine, ranging from early research and clinical trials to manufacturing and safety monitoring. The principles are designed for:
- Developers of medicines
- Marketing authorization applicants and holders
By implementing these guidelines, EMA and FDA aim to enhance international collaboration among regulators, technical standard-setting organizations, and other stakeholders in the field.
Future Development and Enhanced Collaboration
Building on previous collaborations, including the FDA-EU Bilateral meeting in April 2024, this initiative is part of a broader strategy to strengthen EU-US cooperation in novel medical technologies. According to Olivér Várhelyi, the European Commissioner for Health and Animal Welfare, these principles exemplify how both regions can maintain a leading role in global innovation while prioritizing patient safety.
The Promise of AI in Medicine
The use of AI in the pharmaceutical industry has surged recently. The European Commission’s Biotech Act proposal emphasizes AI’s potential as a transformative tool that can expedite the development of safe and effective medicines. The new pharmaceutical legislation facilitates the broader application of AI in regulatory decision-making, enabling innovative AI-driven methods to be tested in controlled settings.
Risk Management and Compliance
For the benefits of AI to be fully realized, it must be managed effectively, with a focus on risk mitigation. The evolving nature of AI technologies necessitates a principles-based approach that helps regulators, pharmaceutical companies, and medicine developers maximize AI’s potential while ensuring compliance with safety regulations.
Ethical Considerations and Global Convergence
With ethics as a foundational element, the EMA continues to seek opportunities for global convergence on AI-related topics. This aligns with their mission to promote the responsible use of AI, as outlined in the European Medicines Agencies Network Strategy (EMANS) for 2028.
As these guiding principles are further developed, they will be supplemented by additional guidance from the EU, considering applicable legal requirements and new legislation in the area of medicines.
In conclusion, the EMA and FDA’s initiative presents a structured foundation for the responsible integration of AI in the drug development process, ensuring that innovation proceeds hand-in-hand with regulatory compliance and patient safety.
For media inquiries, please contact the EMA through the provided channels.
